Docosatetraenoyl ethanolamide (DEA) is an endocannabinoid containing docosatetraenoic acid in place of the arachidonate moiety of AEA. DEA acts on CB1 receptors with potency and efficacy similar to that of AEA.1 However, its specific role and relative importance as a cannabinergic neurotransmitter have not been elucidated.2
1
Felder, C.C., Briley, E.M., Axelrod, J., et al. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA907656-7660(1993).
2
Hanus, L., Gopher, A., Almog, S., et al. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem363032-3034(1993).
Felder, C.C., Briley, E.M., Axelrod, J., et al. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc Natl Acad Sci USA907656-7660(1993).
Hanus, L., Gopher, A., Almog, S., et al. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J Med Chem363032-3034(1993).
Docosatetraenoyl Ethanolamide is available in the following screening
library: